3Malhotra A, Kang BP, Cheung S, et al. Angiotensin II promotes glucose- induced activation of cardiac protein kinase C isozymes and phosphory-lation oftroponin I [J].Diabetes,2001,50:191g-1926.
4Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials [J]. J Am Coil Cardiol,2005,46(5):821-826.
5Bumier M, Branner HR. Angiotensin II receptor antagonist [J]. Lancet,2000, 355:637-645.
6Clasen R, Schupp M, Foryst-Luduig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin [J]. Hypertension, 2005,46( 1): 137-143.
7Benson SC, Pershadsingh HA, Ho I, et al. Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPARmodulating activity [J], Hypertension,2004,43(5):993-1002.
8Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome [J]. Sao Paulo Med J,2001,119(3): 122-127.
9John A, Cohrell MD. Inflammation and diabetic vascular complications [J]. Diabetes Care, 1999,22(12): 1927-1928.
10Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism [J]. Diabetes Care, 1991, 14 (3): 203-209.
